Xencor Inc XNCR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657
Xencor Reports Third Quarter 2026 Financial Results
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor to Present at the 2026 Cantor Global Healthcare Conference
Trading Information
- Previous Close Price
- $35.40
- Day Range
- $34.23–35.69
- 52-Week Range
- $10.38–40.60
- Bid/Ask
- $34.48 / $34.49
- Shares Outstanding
- 75.04M
- Market Cap
- $2.59B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 13.33
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 260
- Website
- https://www.xencor.com
Valuation
Metric | XNCR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.72 |
Price/Sales | 13.33 |
Price/Cash Flow | — |
Price/Earnings
XNCR
Financial Strength
Metric | XNCR |
|---|---|
Quick Ratio | 6.16 |
Current Ratio | 6.54 |
Interest Coverage | −4.82 |
Quick Ratio
XNCR
Profitability
Metric | XNCR |
|---|---|
Return on Assets (Normalized) | −17.19% |
Return on Equity (Normalized) | −24.07% |
Return on Invested Capital (Normalized) | −18.75% |
Return on Assets
XNCR
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|#X>hFW | LOCK|th>?J | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|BLH!#@v | LOCK|TyPl! | $99B | |||
| Moderna Inc MRNA | LOCK|YwJKR%v | LOCK|&h^ | $87B | |||
| argenx SE ADR ARGX | LOCK|x>%WH< | LOCK|<v | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|BwP&^C | LOCK|^H | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Lh%k^x% | LOCK|<fn!p | $31B | |||
| Incyte Corp INCY | LOCK|S^>S^YD | LOCK|kRm | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|<X%r&h | LOCK|xW!Q@ | $21B | |||
| BioNTech SE ADR BNTX | LOCK|Jn!#R#k | LOCK|XFL | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&snSg&K | LOCK|Lf? | $15B |